Funding Opportunity PAR-24-022 from the NIH Guide for Grants and Contracts. This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.

Notice NOT-HG-23-013 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-002 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-23-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is one of three FOAs that will support a comprehensive effort by the National Cancer Institute (NCI) to provide infrastructure to develop and conduct national cancer screening clinical trials and studies through the Cancer Screening Research Network (CSRN). The primary goal of the CSRN is the conduct of multi-center cancer screening trials and studies. This Network is designed to take advantage of large and diverse populations receiving routine care in a variety of healthcare settings. The CSRN will engage these populations in rigorous studies focused on cancer screening to improve early cancer detection and evaluate emerging cancer screening modalities with the ultimate goal of reducing cancer incidence, and cancer-related morbidity and mortality.

Funding Opportunity RFA-CA-23-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is one of three FOAs that will support a comprehensive effort by the National Cancer Institute (NCI) to provide infrastructure to develop and conduct national cancer screening clinical trials and studies through the Cancer Screening Research Network (CSRN). The primary goal of the CSRN is the conduct of multi-center cancer screening trials and studies. This Network is designed to take advantage of large and diverse populations receiving routine care in a variety of healthcare settings. The CSRN will engage these populations in rigorous studies focused on cancer screening to improve early cancer detection and evaluate emerging cancer screening modalities with the ultimate goal of reducing cancer incidence, and cancer-related morbidity and mortality.

Funding Opportunity RFA-CA-23-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is one of three FOAs that will support a comprehensive effort by the National Cancer Institute (NCI) to provide infrastructure to develop and conduct national cancer screening clinical trials and studies through the Cancer Screening Research Network (CSRN). The primary goal of the CSRN is the conduct of multi-center cancer screening trials and studies. This Network is designed to take advantage of large and diverse populations receiving routine care in a variety of healthcare settings. The CSRN will engage these populations in rigorous studies focused on cancer screening to improve early cancer detection and evaluate emerging cancer screening modalities with the ultimate goal of reducing cancer incidence, and cancer-related morbidity and mortality.

Notice NOT-HS-23-003 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-021 from the NIH Guide for Grants and Contracts

Notice NOT-AR-23-007 from the NIH Guide for Grants and Contracts

Notice NOT-HS-23-004 from the NIH Guide for Grants and Contracts

Notice NOT-DK-23-003 from the NIH Guide for Grants and Contracts

Notice NOT-HG-23-014 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-056 from the NIH Guide for Grants and Contracts

Notice NOT-DA-22-064 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-012 from the NIH Guide for Grants and Contracts

Notice NOT-AR-23-011 from the NIH Guide for Grants and Contracts

Notice NOT-AR-23-010 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-125 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-23-059 from the NIH Guide for Grants and Contracts. Sleep and circadian dysfunctions are frequently co-morbid with opioid use disorder (OUD) and may have clinical utility in identifying individuals at risk for poor treatment response and relapse. The goals of this program are a) to uncover novel mechanisms underlying the bidirectional interrelationship between sleep/circadian rhythm and OUD, and b) to reveal new insights into sleep and/or circadian-based predictors of OUD medication treatment response and outcomes.

Funding Opportunity RFA-DA-23-060 from the NIH Guide for Grants and Contracts. Applications are invited from institutions to participate as the Leadership and Data Coordinating Center (LDCC) for the Sleep Predictors of Opioid Use Disorders (OUD) Treatment and Outcomes Program. The overall goals of this program are a) to uncover novel mechanisms underlying the bidirectional interrelationship between sleep/circadian rhythm and OUD, and b) to delineate sleep and/or circadian-based predictors of OUD treatment response and outcomes. The Leadership and Data Coordination Center will lead, coordinate and analyze data for a multi-site common protocol focused on sleep/circadian rhythm measures. The data will be used to develop a predictive model of OUD medication treatment response and outcomes.